Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muranen Taru A, Greco Dario, Blomqvist Carl, Aittomäki Kristiina, Khan Sofia, Hogervorst Frans, Verhoef Senno, Pharoah Paul D P, Dunning Alison M, Shah Mitul, Luben Robert, Bojesen Stig E, Nordestgaard Børge G, Schoemaker Minouk, Swerdlow Anthony, García-Closas Montserrat, Figueroa Jonine, Dörk Thilo, Bogdanova Natalia V, Hall Per, Li Jingmei, Khusnutdinova Elza, Bermisheva Marina, Kristensen Vessela, Borresen-Dale Anne-Lise, NBCS Investigators, Peto Julian, Dos Santos Silva Isabel, Couch Fergus J, Olson Janet E, Hillemans Peter, Park-Simon Tjoung-Won, Brauch Hiltrud, Hamann Ute, Burwinkel Barbara, Marme Frederik, Meindl Alfons, Schmutzler Rita K, Cox Angela, Cross Simon S, Sawyer Elinor J, Tomlinson Ian, Lambrechts Diether, Moisse Matthieu, Lindblom Annika, Margolin Sara, Hollestelle Antoinette, Martens John W M, Fasching Peter A, Beckmann Matthias W, Andrulis Irene L, Knight Julia A, kConFab/AOCS Investigators, Anton-Culver Hoda, Ziogas Argyrios, Giles Graham G, Milne Roger L, Brenner Hermann, Arndt Volker, Mannermaa Arto, Kosma Veli-Matti, Chang-Claude Jenny, Rudolph Anja, Devilee Peter, Seynaeve Caroline, Hopper John L, Southey Melissa C, John Esther M, Whittemore Alice S, Bolla Manjeet K, Wang Qin, Michailidou Kyriaki, Dennis Joe, Easton Douglas F, Schmidt Marjanka K, Nevanlinna Heli
Аннотация
METHODS: Using genotype data from 39,139 (624 1100delC carriers) BC patients and 40,063 (224) healthy controls from 32 BCAC studies, we analyzed the combined risk effects of CHEK2*1100delC and 77 common variants in terms of a polygenic risk score (PRS) and pairwise interaction.
RESULTS: The PRS conferred odds ratios (OR) of 1.59 (95% CI: 1.21-2.09) per standard deviation for BC for CHEK2*1100delC carriers and 1.58 (1.55-1.62) for noncarriers. No evidence of deviation from the multiplicative model was found. The OR for the highest quintile of the PRS was 2.03 (0.86-4.78) for CHEK2*1100delC carriers, placing them in the high risk category according to UK NICE guidelines. The OR for the lowest quintile was 0.52 (0.16-1.74), indicating a lifetime risk close to the population average.
CONCLUSION: Our results confirm the multiplicative nature of risk effects conferred by CHEK2*1100delC and the common susceptibility variants. Furthermore, the PRS could identify carriers at a high lifetime risk for clinical actions.Genet Med advance online publication 06 October 2016.